Sign Up Today and Learn More About Mammoth Biosciences Stock
Invest in or calculate the value of your shares in Mammoth Biosciences or other pre-IPO companies through EquityZen, part of Morgan Stanley.
Mammoth Biosciences Stock (MABI)
Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
About Mammoth Biosciences Stock
Founded
2017
Headquarters
San Francisco, CA, US
Total Funding
379M
Industries
Science and Engineering, Health Care, Biotechnology
Mammoth Biosciences is a developer of a ultracompact CRISPR system for diagnostics, protein discovery, and genome therapeutics. The company identifies Cas enzymes and associated technologies to perform edits in-vivo to offer potentially curative treatments for patients with unmet needs.
Mammoth Biosciences Press Mentions
Stay in the know about the latest news on Mammoth Biosciences
真香现场？CRISPR之母杀入AI蛋白质！一个月前还给AI泼冷水
news • Jul 21, 2026
Mammoth Biosciences to Partner With M42, Abu Dhabi Department of Health on Drug Development
genomeweb • Jun 26, 2026
Mammoth Biosciences to Present at 44th Annual J.P. Morgan Healthcare Conference
biospace • Jan 11, 2026
“All Genetic Diseases Could be Cured within a Decade”, Hears Dubai Future Forum
businesswire • Nov 20, 2025
Cas12 Protein Market Report 2025: Market Led by Thermo Fisher, Bio-Techne and IDT, With APAC Set for Fastest Growth Despite Trade-Driven Supply Challenges - Global Forecast to 2029 and 2034
globenewswire • Nov 04, 2025
Investors in Mammoth Biosciences
Discover investors in Mammoth Biosciences stock and explore their portfolio companies
Mammoth Biosciences Management
Leadership team at Mammoth Biosciences
Co-Founder and CEO
Trevor Martin
Chief Operating Officer and Chief Financial Officer
Elaine Sun
Join now and verify your accreditation status to gain access to:
- Mammoth Biosciences Current Valuation
- Mammoth Biosciences Stock Price
- Mammoth Biosciences Management
- Available deals in Mammoth Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Mammoth Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- Mammoth Biosciences Revenue and Financials
- Mammoth Biosciences Highlights
- Mammoth Biosciences Business Model
- Mammoth Biosciences Risk Factors
- Mammoth Biosciences Research Report from SACRA Research
Mammoth Biosciences Key Facts
- Validation via BioPharma Partnership: In April 2024, Mammoth Biosciences announced a strategic collaboration with Regeneron Pharmaceuticals. The deal reportedly provided $100 million in combined upfront payment and equity investment to codevelop in vivo CRISPR therapies beyond liver targets. By combining Regeneron’s cell-targeted delivery vectors with Mammoth’s ultra-compact Cas nucleases, the alliance helps to validate Mammoth Biosciences' platform potential and strengthens its capital runway.
- Monetization of Diagnostic IP via Out-Licensing: Mammoth Biosciences has streamlined its business model to focus on therapeutics while continuing to monetize its non-therapeutic IP through a non-exclusive licensing deal with VedaBio. The licensing agreement grants VedaBio access to foundational Cas enzyme diagnostic IP for decentralized, amplification-free detection assays, potentially allowing Mammoth Biosciences to capture downstream revenue in the expanding molecular diagnostics market without allocating heavy internal sales resources.
- Therapeutic Pipeline Advancement & Structural Platform Differentiation: Mammoth Biosciences continues to advance its wholly owned in vivo gene-editing pipeline, highlighting preclinical progress for its lead program MB-111 and presenting updates at the 44th Annual J.P. Morgan Healthcare Conference. Because Mammoth Biosciences’ novel Cas enzymes are estimated to be roughly one-third the size of standard Cas9, they aim to overcome traditional viral vector payload restrictions, establishing a clear technological advantage for delivering complex editing tools into hard-to-reach tissues.
- Regulatory Uncertainty and Clinical Execution Risks: As Mammoth aims to move MB-111 into the clinic in 2026, it enters a highly scrutinized regulatory environment. The EU AI Act and new FDA guidance on genomic data provenance mandate transparency in how AI-discovered enzymes are designed and tested. Any preclinical setbacks or delays in obtaining Investigational New Drug (IND) clearance could significantly impact the company’s potential success, particularly as investors shift their focus from "platform potential" to "clinical proof-of-concept."
- Operational Restructuring and Human Capital Risk: In May 2025, Mammoth Biosciences executed a workforce reduction of 24 employees, representing approximately 13% of its staff at the time. This move was part of a broader biopharma trend, as companies narrowed their focus to lead candidates to preserve cash in a challenging capital market. While intended to streamline the path for its lead drug candidate, MB-111, such layoffs can lead to internal disruption, especially as well-funded rivals like Scribe Therapeutics and Metagenomi compete for the same specialized talent in metagenomics and protein engineering.
- Intense Market Competition in CRISPR Diagnostics: While Mammoth maintains a strong patent portfolio for ultra-small Cas systems, the CRISPR-based diagnostics market is becoming intensely competitive. Mammoth faces emerging threats from specialized global competitors like CrisprBits (India) and CASPR Biotech (Argentina/U.S.), which are developing low-cost, portable CRISPR diagnostics tailored for resource-constrained settings. This intensifying competition could pressure Mammoth’s market share and pricing power in the diagnostics segment.
Trading Mammoth Biosciences Stock
How to invest in Mammoth Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Mammoth Biosciences through EquityZen funds. These investments are made available by existing Mammoth Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Mammoth Biosciences stock?
Shareholders can sell their Mammoth Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 56K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
